Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 45,700 shares, a decrease of 41.3% from the December 31st total of 77,800 shares. Based on an average daily trading volume, of 101,800 shares, the short-interest ratio is presently 0.4 days.

Insider Transactions at Abrdn Life Sciences Investors

In other news, major shareholder Saba Capital Management, L.P. sold 11,674 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $14.12, for a total transaction of $164,836.88. Following the completion of the sale, the insider now owns 3,418,349 shares in the company, valued at $48,267,087.88. This represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 28,663 shares of company stock worth $406,827. Company insiders own 10.06% of the company's stock.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Several institutional investors and hedge funds have recently added to or reduced their stakes in HQL. Stephens Inc. AR increased its holdings in Abrdn Life Sciences Investors by 7.6% in the third quarter. Stephens Inc. AR now owns 12,707 shares of the company's stock valued at $192,000 after buying an additional 896 shares in the last quarter. Sanctuary Advisors LLC increased its stake in Abrdn Life Sciences Investors by 11.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company's stock valued at $183,000 after purchasing an additional 1,355 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in Abrdn Life Sciences Investors during the third quarter worth $30,000. BankPlus Trust Department purchased a new position in shares of Abrdn Life Sciences Investors in the fourth quarter valued at $28,000. Finally, Janney Montgomery Scott LLC lifted its stake in Abrdn Life Sciences Investors by 7.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company's stock valued at $1,199,000 after buying an additional 6,200 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company's stock.

Abrdn Life Sciences Investors Stock Up 2.1 %

Shares of HQL stock traded up $0.30 during mid-day trading on Wednesday, hitting $14.33. The stock had a trading volume of 209,639 shares, compared to its average volume of 126,519. The company's 50-day simple moving average is $13.77 and its 200-day simple moving average is $14.58. Abrdn Life Sciences Investors has a fifty-two week low of $12.76 and a fifty-two week high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Thursday, November 21st were given a $0.50 dividend. The ex-dividend date was Thursday, November 21st. This represents a $2.00 dividend on an annualized basis and a yield of 13.96%. This is an increase from Abrdn Life Sciences Investors's previous quarterly dividend of $0.49.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.